GLP-1 Market
LLY $1406.29 ▼ -1.8% NVO $40.70 ▼ -2.2% PFE $28.41 ▼ -1.6% VKTX $26.65 ▼ -0.6% KLRA $12.08 ▼ -3.9% GPCR $18.06 ▼ -2.7% RHHBY $60.95 ▲ +1.1%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

OPT101

OPT101

Company
Op-T LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for OPT101 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06964087

    Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

    Not yet reported Op-T LLC 72 participants Est. completion 2028-08-19 5 sites Stand-alone
    Other conditions: Type I Diabetes
    View official trial listing →
  • Completed NCT NCT04589403

    1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

    Not yet reported Op-T LLC 14 participants Est. completion 2021-09-27 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05428943

    OPT101 in Type 1 Diabetes Patients

    Not yet reported Op-T LLC 24 participants Est. completion 2024-02-21 2 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Not yet recruiting NCT NCT06669403

    OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

    Not yet reported Op-T LLC 26 participants Est. completion 2026-05 1 site Stand-alone
    Other conditions: Sepsis, Community Acquired Pneumonia (CAP)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.